Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * ABG WTT-MedAvail Ltd	2. Date of Event Requiring Statement (MM/DD/YYYY) 11/18/2020	3. Issuer Name and Ticker or Trading Symbol MedAvail Holdings, Inc. [MDVL]
(Last)        (First)        (Middle) UNIT 3002-3004, 30TH FLOOR, GLOUCESTER TOWER, THE LANDMARK, CENTRAL	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                          ___X___ 10% Owner _____ Officer (give title below)        _____ Other (specify below)
(Street) HONG KONG, K3        (City)              (State)              (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) ___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3782080	I	See footnotes (1)
Common Stock	2835090	I	See footnotes (2)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:
(1)	These securities are held of record by ABG WTT-MedAvail Limited ("ABG WTT"). ABG WTT is wholly owned by Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. Voting and investment decisions with respect to any securities held of record by ABG WTT are made by the investment committee of ABG-WTT Global Life Science Capital Partners GP Limited, which is the general partner of ABG-WTT Global Life Science Capital Partners GP, L.P., which is the general partner of Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. As such, each of the foregoing entities may be deemed to share beneficial ownership of the shares held by ABG-WTT. Each of them disclaims any such beneficial ownership.
(2)	These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. ("MedAlpha"). Mr. Fan Yu is the sole shareholder of ABG Management Ltd., which is the sole member of each of Ally Bridge MedAlpha Management GP, LLC and Ally Bridge Group (NY) LLC. Ally Bridge Group (NY) LLC and Ally Bridge MedAlpha Management L.P., acting through its general partner Ally Bridge MedAlpha Management GP, LLC, manage MedAlpha's investments. As such, each of the foregoing entities and Mr. Fan Yu may be deemed to share beneficial ownership of the shares held of record by MedAlpha. Each of them disclaims any such beneficial ownership.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
ABG WTT-MedAvail Ltd UNIT 3002-3004, 30TH FLOOR GLOUCESTER TOWER, THE LANDMARK, CENTRAL HONG KONG, K3		X
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P. UNIT 3002-3004, 30TH FLOOR GLOUCESTER TOWER, THE LANDMARK, CENTRAL HONG KONG, K3		X
ABG-WTT Global Life Science Capital Partners GP, L.P. UNIT 3002-3004, 30TH FLOOR GLOUCESTER TOWER, THE LANDMARK, CENTRAL HONG KONG, K3		X
ABG-WTT Global Life Science Capital Partners GP Ltd UNIT 3002-3004, 30TH FLOOR GLOUCESTER TOWER, THE LANDMARK, CENTRAL HONG KONG, K3		X
ABG Management Ltd. UNIT 3002-3004, 30TH FLOOR GLOUCESTER TOWER, THE LANDMARK, CENTRAL HONG KONG, K3		X
Yu Fan UNIT 3002-3004, 30TH FLOOR GLOUCESTER TOWER, THE LANDMARK, CENTRAL HONG KONG, K3		X
Ally Bridge MedAlpha Master Fund L.P. 430 PARK AVENUE, 12TH FLOOR, NEW YORK, NY 10022		X
Ally Bridge MedAlpha Management L.P. 430 PARK AVENUE, 12TH FLOOR, NEW YORK, NY 10022		X
Ally Bridge MedAlpha Management GP, LLC 430 PARK AVENUE, 12TH FLOOR, NEW YORK, NY 10022		X
Ally Bridge Group (NY) LLC 430 PARK AVENUE, 12TH FLOOR, NEW YORK, NY 10022		X

Signatures
Ally Bridge Group-WTT Global Life Science Capital Partners, L.P., By: ABG-WTT Global Life Science Capital Partners GP, L.P., its general partner, By: ABG-WTT Global Life Science Capital Partners GP Limited, its general partner, By: /s/ Fan Yu, Director		11/30/2020
**Signature of Reporting Person		Date
ABG-WTT Global Life Science Capital Partners GP, L.P., By: ABG-WTT Global Life Science Capital Partners GP Limited, its general partner, By: /s/ Fan Yu, Director		11/30/2020
**Signature of Reporting Person		Date
ABG-WTT Global Life Science Capital Partners GP Limited, By: /s/ Fan Yu, Director		11/30/2020
**Signature of Reporting Person		Date
Ally Bridge MedAlpha Master Fund L.P., By: Ally Bridge MedAlpha General Partner L.P., its general partner, By: Ally Bridge MedAlpha GP, LLC, its general partner, By: /s/ Fan Yu, Manager		11/30/2020
**Signature of Reporting Person		Date
Ally Bridge MedAlpha Management L.P., By: Ally Bridge MedAlpha Management GP, LLC, its general partner, By: ABG Management Ltd., its managing member, By: /s/ Fan Yu, Director		11/30/2020
**Signature of Reporting Person		Date
Ally Bridge MedAlpha Management GP, LLC, By: ABG Management Ltd., its managing member, By: /s/ Fan Yu, Director		11/30/2020
**Signature of Reporting Person		Date
Ally Bridge Group (NY) LLC, By: ABG Management Ltd., its managing member, By: /s/ Fan Yu, Director		11/30/2020
**Signature of Reporting Person		Date
ABG Management Ltd., By: /s/ Fan Yu, Director		11/30/2020
**Signature of Reporting Person		Date
ABG WTT-MedAvail Limited, By: /s/ Charles Chon, Director		11/30/2020
**Signature of Reporting Person		Date
/s/ Fan Yu		11/30/2020
**Signature of Reporting Person		Date